Sativa's CBD Therapeutics Business Achieves the Highest Food Safety Standards
Sativa Wellness Group has announced its Polish extraction facility has achieved accreditation for its HACCP system and compliance with GMP and GHP standards. This positions the company to adhere to high quality and safety regulations in food manufacturing.
With increasing demand for its CBD products, Sativa Wellness aims to boost its production capacity amid positive trends in the European CBD market, especially following a pivotal court ruling regarding CBD classification.
- Accreditation of HACCP system securing compliance with GMP and GHP standards.
- Increased demand for broad cannabinoid spectrum distillate bulk ingredients.
- Anticipated ongoing demand for CBD products in the UK and Europe.
- None.
VANCOUVER, BC / ACCESSWIRE / March 1, 2021 / Sativa Wellness Group Inc. (CSE:SWEL)(OTC PINK:SCNNF)(FSE:484)(AQSE:SWEL) ("Sativa Wellness" or the "Company"). Sativa Wellness is pleased to announce that its Polish extraction facility has secured accreditation of its Hazard Analysis and Critical Control Point ("HACCP") system from global quality and certification company LL-C Group, and confirmation that its operations meet the requirements of Good Manufacturing Practice ("GMP") and Good Hygiene Practice ("GHP") standards for food manufacturing.
This latest achievement, alongside the Company's recent announcement regarding its Novel Food submission, underpins Sativa's commitment to continually deliver the highest level of regulatory compliance and product quality - 'CBD you can trust'.
The Company's CBD therapeutics division continues to position itself as a leader in the European and global CBD space, and comprises a seed to consumer integrated supply chain. The Company has selected grow partners cultivating the highest quality European seed strain hemp, a state of the art extraction facility in Poland producing Novel Food grade bulk wholesale ingredients and finished consumer products, and a UK manufacturing facility. Its Goodbody CBD brands are sold online and retail as well as selling through white label distribution channels. The Company's commitment to quality is underpinned by Phytovista Laboratories, the UK's premier specialist laboratory for CBD and hemp-based products.
The Company is experiencing increasing demand for its broad cannabinoid spectrum Distillate bulk ingredients, and is augmenting its production schedule and processes to increase capacity. It anticipates strong ongoing demand for bulk ingredients and finished products across the UK and Europe in-light of the European Union's highest court ruling that CBD (Cannabidiol) is not a narcotic drug, and the Novel Food authorisation process.
Geremy Thomas, Executive Chairman, says: "Quality and product safety are paramount within our organisation. Our adherence to these international safety standards assures our customers that we provide them with safe and quality products - CBD you can trust. We welcome the clarity from UK and European authorities that sets out a clear regulatory pathway, that will allow consumers to benefit from un-fettered access to CBD products."
The Directors of the Company accept responsibility for the contents of this announcement.
Further information regarding the Company can be found at www.sedar.com.
On behalf of the Board of Directors,
Geremy Thomas Executive Chairman Sativa Wellness Group Inc. +44 (0) 20 7971 1255 | Joseph Colliver Chief Financial Officer Sativa Wellness Group Inc. +44 (0) 20 7971 1255 |
Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Sativa Wellness' control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" "plan is" or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur", "will be achieved" or "shortly". The forward-looking information and forward-looking statements contained herein include, but are not limited to information concerning the European CBD market and the Company's CBD operations and plans.
Although Sativa Wellness believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that the Company will be the leader in the European CBD market, that it will be able to capitalize on the CBD market, that it will continue operating in the CBD market, that the Company will be able to monetize any demand for bulk CBD and that the Company will be able to increase its production of CBD. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and Sativa does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
SOURCE: Sativa Wellness Group Inc.
View source version on accesswire.com:
https://www.accesswire.com/632523/Sativas-CBD-Therapeutics-Business-Achieves-the-Highest-Food-Safety-Standards
FAQ
What recent achievement did Sativa Wellness Group announce for its extraction facility?
How is Sativa Wellness Group positioned in the European CBD market?
What are the implications of the court ruling on CBD classification for Sativa Wellness Group?
What is the impact of the Novel Food submission mentioned by Sativa Wellness Group?
